Kaspofungin

Caspofungin, the active ingredient in Kaspofungin, is an echinocandin presented as an oral formulation for systemic use in severe fungal infections. It treats invasive candidiasis, esophageal candidiasis and invasive aspergillosis in adult patients requiring antifungal therapy.

GNH USA supplies Kaspofungin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and offering reliable global distribution with timely delivery and regulatory support for each market.

Kaspofungin is an echinocandin antifungal indicated for several serious fungal infections.

- Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: eradicates Candida infection of the esophagus, relieving dysphagia and pain. - Invasive aspergillosis: provides therapeutic activity against Aspergillus species in immunocompromised patients.

Caspofungin may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Fever: transient elevation of body temperature during therapy. - Nausea: mild to moderate stomach upset. - Headache: occasional dull or throbbing head pain. - Rash: skin redness or mild itching.

Serious or Rare Side Effects: - Hepatotoxicity: significant elevation of liver enzymes or jaundice. - Severe hypersensitivity: anaphylactic reactions requiring immediate discontinuation. - Cardiac arrhythmia: rare disturbances in heart rhythm. - Acute renal failure: sudden loss of kidney function in susceptible individuals.

When prescribing Kaspofungin, clinicians should consider several safety precautions to minimize risk.

- Liver function monitoring: assess hepatic enzymes before and during therapy. - Renal function assessment: evaluate kidney status, especially in patients with pre‑existing impairment. - Hypersensitivity risk: discontinue if signs of allergic reaction such as rash or anaphylaxis appear. - Cardiac considerations: use cautiously in patients with heart failure or significant fluid overload. - Dose adjustment: consider reduced dosing in severe hepatic impairment. - Store at ambient temperature: keep in original container, protect from moisture and light.

Caspofungin can interact with other medicines, requiring attention to avoid altered drug exposure.

Major Interactions (Avoid): - Cyclosporine: co‑administration may increase cyclosporine blood concentrations, requiring dose adjustment. - Tacrolimus: concurrent use can raise tacrolimus levels, increasing risk of toxicity.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce caspofungin exposure, potentially decreasing efficacy. - Azole antifungals (e.g., fluconazole): may increase caspofungin levels, necessitating therapeutic monitoring. - Bile acid sequestrants: can lower absorption of oral caspofungin; separate dosing times are recommended.